Sweet Stuart C
Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri.
Respir Care. 2017 Jun;62(6):776-798. doi: 10.4187/respcare.05304.
Pediatric lung transplant is a viable option for treatment of end-stage lung disease in children, with > 100 pediatric lung transplants reported to the Registry of the International Society of Heart and Lung Transplantation each year. Long-term success is limited by availability of donor organs, debilitation as a result of chronic disease, impaired mucus clearance resulting from both surgical and pharmacologic interventions, increased risk for infection resulting from immunosuppression, and most importantly late complications, such as chronic lung allograft dysfunction. Opportunities for investigation and innovation remain in all of these domains: (1) Ex vivo lung perfusion is a promising technology with the potential for increasing the lung donor pool, (2) evolving extracorporeal support strategies coupled with effective rehabilitation will effectively bridge critically ill patients to transplant, and most importantly, (3) research efforts intended to increase our understanding of the underlying mechanisms of chronic lung allograft dysfunction will ultimately lead to the development of effective therapies to prevent or treat the variety of chronic lung allograft dysfunction presentations.
小儿肺移植是治疗儿童终末期肺病的一种可行选择,每年向国际心肺移植学会登记处报告的小儿肺移植超过100例。长期成功受到供体器官可用性、慢性疾病导致的身体虚弱、手术和药物干预导致的黏液清除受损、免疫抑制导致的感染风险增加以及最重要的晚期并发症(如慢性肺移植功能障碍)的限制。在所有这些领域仍有研究和创新的机会:(1)体外肺灌注是一项有前景的技术,有可能增加肺供体库;(2)不断发展的体外支持策略与有效的康复相结合,将有效地使重症患者过渡到移植;最重要的是,(3)旨在增进我们对慢性肺移植功能障碍潜在机制理解的研究努力,最终将导致开发出预防或治疗各种慢性肺移植功能障碍表现的有效疗法。